17 May 2021

17th Amendment to the Foreign Trade and Payments Ordinance now in force

Fourth Amendment for tightening Investment Screening within one year.

On 1 May 2021, the 17th Amendment to the Foreign Trade and Payments Ordinance entered into force. This is already the fourth change to Germany’s investment screening under foreign trade law within one year, creating additional hurdles for non-EU parties when it comes to investing in German companies. This amendment includes an expansion to the reporting obligation for investments representing a stake of at least 20%, now covering additional industry sectors in next generation technologies, such as artificial intelligence, autonomous driving, semiconductors, optoelectronics, and quantum technology.

Our GSK Update summarizes the key changes under this amendment and illuminates what investors who are domiciled outside of the EU will need to keep in mind in the future when investing in German businesses.

Print


Press contact
presse@gsk.de
+49 30 203907-7763

Back

GSK Updates
  • 24 June 2022

    GSK Update: Accelerated construction of LNG terminals in Germany

    Read more
  • 06 May 2022

    GSK Update: Whistleblowing 2.0: What will the second draft of the Whistleblower Protection Act bring along?

    Read more
  • 25 April 2022

    GSK Update: Ban on public contracts with Russian companies

    Read more
Contact person

Dr. Andreas Bauer, LL.M.

Partner*

+49 89 288174-74

andreas.bauer@gsk.de

* Partner: a partner within the meaning of the German Partnership Companies Act.
   Local Partner: not a partner within the meaning of the German Partnership Companies Act.
CO2 Neutral